Nevro (NVRO) | Financial Analysis & Statements
Nevro Corp. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2024Income Metrics
Revenue
105.5M
Gross Profit
65.9M
62.45%
Operating Income
-23.0M
-21.79%
Net Income
-53.1M
-50.32%
EPS (Diluted)
$-1.41
Balance Sheet Metrics
Total Assets
553.8M
Total Liabilities
322.8M
Shareholders Equity
231.0M
Debt to Equity
1.40
Cash Flow Metrics
Operating Cash Flow
-30.4M
Free Cash Flow
16.6M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2024
Annual Income Flow
2024
Nevro Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 408.5M | 425.2M | 406.4M | 386.9M | 362.0M |
| Cost of Goods Sold | 139.0M | 135.1M | 130.0M | 120.9M | 112.1M |
| Gross Profit | 269.5M | 290.1M | 276.4M | 266.0M | 249.9M |
| Gross Margin % | 66.0% | 68.2% | 68.0% | 68.8% | 69.0% |
| Operating Expenses | |||||
| Research & Development | 51.5M | 54.4M | 53.1M | 47.7M | 45.6M |
| Selling, General & Administrative | 309.8M | 334.7M | 322.1M | 309.3M | 267.2M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 361.3M | 389.1M | 375.2M | 357.0M | 312.8M |
| Operating Income | -94.7M | -99.3M | -98.8M | -90.9M | -62.9M |
| Operating Margin % | -23.2% | -23.4% | -24.3% | -23.5% | -17.4% |
| Non-Operating Items | |||||
| Interest Income | 13.3M | 14.2M | 4.0M | 671.0K | 3.0M |
| Interest Expense | 26.9M | 8.0M | 6.4M | 19.7M | 21.8M |
| Other Non-Operating Income | -4.1M | -4.7M | 105.5M | -20.8M | -495.0K |
| Pre-tax Income | -112.3M | -97.9M | 4.3M | -130.8M | -82.2M |
| Income Tax | 1.1M | -5.6M | 1.3M | 534.0K | 868.0K |
| Effective Tax Rate % | 0.0% | 0.0% | 29.6% | 0.0% | 0.0% |
| Net Income | -113.4M | -92.2M | 3.0M | -131.4M | -83.1M |
| Net Margin % | -27.8% | -21.7% | 0.7% | -34.0% | -22.9% |
| Key Metrics | |||||
| EBITDA | -67.7M | -74.2M | -84.0M | -82.4M | -52.2M |
| EPS (Basic) | - | $-2.56 | $0.08 | $-3.77 | $-2.47 |
| EPS (Diluted) | - | $-2.56 | $0.08 | $-3.77 | $-2.47 |
| Basic Shares Outstanding | - | 35981431 | 35317644 | 34823258 | 33677641 |
| Diluted Shares Outstanding | - | 35981431 | 35317644 | 34823258 | 33677641 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Nevro Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 94.5M | 104.2M | 120.4M | 34.7M | 44.6M |
| Short-term Investments | 198.0M | 218.5M | 254.0M | 327.3M | 543.4M |
| Accounts Receivable | 71.9M | 79.4M | 78.9M | 70.5M | 77.7M |
| Inventory | 103.3M | 118.7M | 99.6M | 93.5M | 83.3M |
| Other Current Assets | 8.3M | 10.1M | 10.0M | 5.2M | 4.2M |
| Total Current Assets | 476.0M | 530.9M | 562.9M | 531.2M | 753.1M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 36.8M | 24.4M | 24.9M | 26.3M | 25.2M |
| Goodwill | 24.4M | 103.7M | 0 | - | - |
| Intangible Assets | 24.4M | 27.4M | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 5.7M | 5.8M | 3.8M | 5.1M | 4.6M |
| Total Non-Current Assets | 77.8M | 104.8M | 39.5M | 43.3M | 36.3M |
| Total Assets | 553.8M | 635.7M | 602.4M | 574.5M | 789.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 24.5M | 22.5M | 26.8M | 32.0M | 23.1M |
| Short-term Debt | 38.0M | - | - | - | 168.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 2.1M | 15.6M | 5.2M | 4.7M | 4.0M |
| Total Current Liabilities | 102.9M | 83.4M | 79.2M | 82.2M | 239.2M |
| Non-Current Liabilities | |||||
| Long-term Debt | 213.2M | 216.1M | 197.2M | 166.7M | 158.5M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 5.8M | 14.3M | 2.2M | 22.0M | 3.3M |
| Total Non-Current Liabilities | 219.9M | 259.2M | 199.3M | 188.7M | 161.8M |
| Total Liabilities | 322.8M | 342.6M | 278.5M | 270.9M | 401.0M |
| Equity | |||||
| Common Stock | 38.0K | 36.0K | 35.0K | 35.0K | 35.0K |
| Retained Earnings | -812.8M | -699.4M | -607.2M | -624.2M | -492.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 231.0M | 293.1M | 323.9M | 303.6M | 388.5M |
| Key Metrics | |||||
| Total Debt | 251.2M | 216.1M | 197.2M | 166.7M | 327.2M |
| Working Capital | 373.1M | 447.5M | 483.7M | 449.0M | 513.9M |
Balance Sheet Composition
Nevro Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -113.4M | -92.2M | 3.0M | -131.4M | -83.1M |
| Depreciation & Amortization | 14.1M | 11.5M | 10.3M | 8.7M | 8.2M |
| Stock-Based Compensation | 51.2M | 56.9M | 56.8M | 44.4M | 42.7M |
| Working Capital Changes | 19.4M | -36.9M | -46.7M | 13.7M | 12.5M |
| Operating Cash Flow | -26.0M | -58.5M | 24.6M | -51.4M | -4.8M |
| Investing Activities | |||||
| Capital Expenditures | -9.8M | -8.6M | -7.5M | -12.3M | -6.0M |
| Acquisitions | -45.0K | -38.0M | 0 | 0 | 7.5M |
| Investment Purchases | -159.7M | -191.1M | -268.2M | -446.9M | -668.4M |
| Investment Sales | 184.1M | 230.6M | 340.0M | 661.0M | 297.0M |
| Investing Cash Flow | 14.6M | -7.2M | 64.3M | 201.7M | -369.9M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 0 | 200.0M | 0 | 0 | 189.8M |
| Debt Repayment | 0 | -146.4M | 0 | -172.5M | 0 |
| Financing Cash Flow | -4.2M | 49.5M | -2.5M | -169.4M | 312.0M |
| Free Cash Flow | -29.2M | -67.4M | 17.1M | -54.2M | -4.8M |
| Net Change in Cash | -15.6M | -16.2M | 86.5M | -19.0M | -62.7M |
Cash Flow Trend
Nevro Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
144.40
Forward P/E
-2.26
Price to Book
0.96
Price to Sales
0.55
PEG Ratio
-2.26
Profitability Ratios
Profit Margin
-27.77%
Operating Margin
-21.79%
Return on Equity
-43.29%
Return on Assets
-9.95%
Financial Health
Current Ratio
4.62
Debt to Equity
108.86
Beta
0.82
Per Share Data
EPS (TTM)
$-3.06
Book Value per Share
$6.11
Revenue per Share
$11.02
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NVRO | 224.1M | 144.40 | 0.96 | -43.29% | -27.77% | 108.86 |
| Abbott Laboratories | 160.7B | 25.97 | 3.09 | 12.36% | 13.90% | 26.79 |
| Boston Scientific | 97.6B | 27.49 | 4.02 | 11.84% | 17.29% | 48.92 |
| Zimvie | 535.7M | -20.20 | 1.30 | -4.76% | -4.39% | 56.82 |
| MaxCyte | 92.1M | -2.07 | 0.55 | -23.63% | -135.14% | 10.46 |
| Tactile Systems | 556.2M | 30.45 | 2.56 | 8.77% | 5.79% | 7.29 |
Financial data is updated regularly. All figures are in the company's reporting currency.
